KRAS and neoplasm: In this study, we observed that KRAS-mutant and KRAS-WT CRC cell lines showed similar sensitivity to reovirus-activated NK cell killing, and furthermore, tumor cells with both high and low EGFR expression were equally sensitive to cetuximab-induced ADCC, thus overcoming these obstacles to monotherapy.